Cardiac chymase converts rat proAngiotensin-12 (PA12) to angiotensin II: effects of PA12 upon cardiac haemodynamics

Cardiovasc Res. 2009 Apr 1;82(1):40-50. doi: 10.1093/cvr/cvp003. Epub 2009 Jan 15.

Abstract

Aims: The aim of this study was to observe the direct physiological and biochemical cardiac effects in response to a newly identified putative component of the renin-angiotensin system, proangiotensin-12 (PA12); and investigate whether PA12 can serve as a substrate for Angiotensin II (AngII) generation.

Methods and results: The direct cardiac actions of PA12 and its role as a substrate for chymase-dependent AngII generation were investigated in Sprague-Dawley rats using an isolated heart model of cardiac ischaemia-reperfusion injury. PA12 potently constricted coronary arteries with no significant effect on left-ventricular contractility. PA12 impaired recovery from global ischaemia, maintaining coronary constriction and markedly increasing release of creatine kinase and troponin I (TnI), indicating greater myocardial injury. Analysis of perfusate collected after transcardiac passage revealed a marked increase in AngII production from hearts infused with PA12. Cardiac AngII production was not blocked by angiotensin-converting enzyme inhibitors, whereas inhibition of chymase with chymostatin significantly reduced AngII production and attenuated PA12-induced vasoconstriction and myocardial damage following ischaemia. Furthermore, Angiotensin II type 1 receptor (AT(1)R) blockade abolished PA12 activity. In vitro, PA12 was efficiently and precisely converted to AngII as assessed on reverse phase-high performance liquid chromatography coupled to tandem mass spectrometry. This conversion was blocked by chymostatin.

Conclusion: PA12 may act as a circulating substrate for cardiac chymase-mediated AngII production, in contrast to ACE-mediated AngII production from AngI.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Angiotensin II / metabolism*
  • Angiotensin II Type 1 Receptor Blockers / pharmacology
  • Angiotensin-Converting Enzyme Inhibitors / pharmacology
  • Angiotensinogen / metabolism*
  • Animals
  • Atrial Natriuretic Factor / metabolism
  • Biomarkers / metabolism
  • Blood Pressure
  • Chromatography, High Pressure Liquid
  • Chymases / antagonists & inhibitors
  • Chymases / metabolism*
  • Coronary Vessels / metabolism
  • Coronary Vessels / physiopathology
  • Creatine Kinase / metabolism
  • Hemodynamics* / drug effects
  • Male
  • Myocardial Contraction
  • Myocardial Reperfusion Injury / enzymology*
  • Myocardial Reperfusion Injury / pathology
  • Myocardial Reperfusion Injury / physiopathology
  • Myocardium / enzymology*
  • Myocardium / pathology
  • Oligopeptides / pharmacology
  • Peptide Fragments / metabolism*
  • Perfusion
  • Rats
  • Rats, Sprague-Dawley
  • Renin-Angiotensin System* / drug effects
  • Serine Proteinase Inhibitors / pharmacology
  • Tandem Mass Spectrometry
  • Time Factors
  • Troponin I / metabolism
  • Vasoconstriction
  • Ventricular Function, Left

Substances

  • Angiotensin II Type 1 Receptor Blockers
  • Angiotensin-Converting Enzyme Inhibitors
  • Biomarkers
  • Oligopeptides
  • Peptide Fragments
  • Serine Proteinase Inhibitors
  • Troponin I
  • proangiotensin-12, rat
  • Angiotensinogen
  • Angiotensin II
  • Atrial Natriuretic Factor
  • chymostatin
  • Creatine Kinase
  • Chymases